Back to trial details

Intake questionnaire

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Applying to Atlanta Neuroscience Institute · Atlanta, Georgia

Answer a few short questions to share with the research team.

0 of 3 answered

1. Are you between 18 and 65 years old?
2. Have you been diagnosed with Multiple Sclerosis?
3. Are you able to travel to Atlanta for study visits?